Aytu biopharma reports record revenues, record prescriptions, and highest adjusted ebitda in company history for the fourth quarter of fiscal year 2023

Q4 2023 net revenue of $30.7 million; adjusted ebitda of $7.7 million record q4 2023 total prescriptions increased 32% compared to q4 2022 rx segment net revenue of $23.3 million and adjusted ebitda of $8.3 million in q4 2023 company to host conference call today at 4:30pm et englewood, co / accesswire / september 27, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fourth quarter and fiscal year ended june 30, 2023. q4 2023 commercial highlights (3 months ending june 30, 2023) total net revenue was $30.7 million, an increase of 12% from the $27.4 million in net revenue in the year-ago quarter and the highest in company history.
AYTU Ratings Summary
AYTU Quant Ranking